Some startups are born in Silicon Valley garages. Rivanna Medical was born in an attic, with a toaster oven doubling as a lab tool and a deer spine standing in for test subjects. That’s not mythology, that’s Will Mauldin, Ph.D., and Kevin Owen, Ph.D., hacking together early prototypes before most people even thought portable AI-driven ultrasound was possible. Fast-forward fifteen years, and Rivanna isn’t a scrappy side project anymore; it’s a company with FDA-cleared devices in hospitals across five continents, more than $90 million in funding, and a technology platform that takes some of medicine’s most complex needle-guided procedures and makes them precise, efficient, and safer.
The latest move? An $800,000 grant from the Virginia Catalyst Program, matched with $1.6 million from undisclosed sources. Add that to BARDA’s $59 million in awards to date, NIH’s $5 million in grants, and private investment, and the total war chest tops $90 million. Non-dilutive money fueling hard science is the kind of quiet advantage most founders dream about, but few ever master. Rivanna did.
What makes this story compelling is not just the capital, it’s the timing. Last month, the company’s Accuro 3S received FDA 510(k) clearance. This is the world’s first AI-powered ultrasound platform designed to guide spinal needle interventions in real time. It leverages SpineNav-AI to automatically recognize spinal landmarks and dual-array probes to track needles continuously. In a world where anesthesiologists often have to rely on feel and guesswork, Rivanna is trading hunches for precision. That’s not incremental innovation; it’s a paradigm shift hiding in plain sight.
The leadership roster shows why this team can pull it off. Will Mauldin drives the vision as CEO and Chairman. Kevin Owen still has his fingerprints all over the architecture as Co-Founder and Board Member. Adam Dixon, Ph.D., as CTO, is building technology that not only meets regulatory standards but integrates seamlessly into clinical workflows. The bench runs deep: Craig Loomis on product management, Delphine Le Roux on market access, Paul Sheeran steering R&D, Mikel Lewis handling manufacturing, Mike Mast on finance, and Vicki Brothers in marketing. That’s not just a founding duo grinding in isolation; it’s a professional squad scaling science into impact.
The bigger takeaway here is one every founder should clock. Rivanna didn’t chase hype rounds or vanity metrics. They went after contracts, grants, and validation from institutions like BARDA, NIH, and FDA. They built credibility brick by brick until hospitals trusted them with patients. And now, with UVA and VCU running multi-site clinical studies, their Accuro platform is set to launch commercially in late 2025. It’s a blueprint in patience, persistence, and precision.
The irony is baked into the name. Rivanna, a river in Virginia, cuts its own path through rock over time. This company is doing the same in healthcare: slow, steady, and impossible to ignore once the channel is carved. When anesthesia and pain management are billion-dollar markets begging for accuracy, Rivanna isn’t chasing the wave. They’re shaping the riverbed the rest will flow through.
